Multistrain Probiotics: The Present Forward the Future

Probiotics, Prebiotics, and Synbiotics: Bioactive Foods in Health Promotion

Volumn , Issue , 2016, Pages 279-302

  Giacchi, Valentina ^a   Sciacca, Pietro ^a   Betta, Pasqua ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Intestinal bacteria; Microbiota modulation; Multistrain probiotics; Safety; Therapeutic effects

Indexed keywords

EID: 84967012437     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-802189-7.00019-8     Document Type: Chapter

References (238)

1. Abrahamsson T.R., Jakobsson H.E., Andersson A.F., Björkstén B., Engstrand L., Jenmalm M.C. Low gut microbiota diversity in early infancy precedes asthma at school age. Clin. Exp. Allergy 2013, 44(6):842-850.
2. Alakomi H.L., Skytta E., Saarela M., Mattila-Sandholm T., Latva-Kala K., Helander I.M. Lactic acid permeabilizes gram-negative bacteria by disrupting the outer membrane. Appl. Environ. Microbiol. 2000, 66:2001-2005.
3. AlFaleh K., Anabrees J., Bassler D., Al-Kharfi T. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst. Rev. 2011, 16(3):CD005496. Art. No.: CD005496. 10.1002/14651858.CD005496.pub3.
4. Anderson R.C., Cookson A.L., McNabb W.C., Park Z., McCann M.J., Kelly W.J., Roy N.C. Lactobacillus plantarum MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formation. BMC Microbiol. 2010, 10:316.
5. Angelakis E., Merhej V., Raoult D. Related actions of probiotics and antibiotics on gut microbiota and weight modification. Lancet Infect. Dis. 2013, 13:889-899.
6. Anukam K.C., Gregor Reid G. Probiotics: 100 years (1907-2007) After Elie Metchnikoff's Observation. Communicating Current Research and Educational Topics and Trends in Applied Microbiology 2007, 466-474. Formatex. A. Méndez-Vilas (Ed.).
7. Applegate J.A., Fischer Walker C.L., Ambikapathi R., Black R.E. Systematic review of probiotics for the treatment of community-acquired acute diarrhea in children. BMC Public Health 2013, 13(Suppl. 3):S16.
8. Arvola T., Laiho K., Torkkeli S., Mykkδnen H., Salminen S., Maunula L., Isolauri E. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics 1999, 104. e64.
9. Barone C., Pettinato R., Avola E., Alberti A., Greco D., Failla P., Romano C. Comparison of three probiotics in the treatment of acute diarrhea in mentally retarded children. Minerva Pediatr. 2000, 52(3):161e5.
10. Beachey E.H. Bacterial adherence: adhesin-receptor interactions mediating the attachment of bacteria to mucosal surfaces. J. Infect. Dis. 1981, 143:325-345.
11. Bermudez-Brito M., Plaza-Díaz J., Muñoz-Quezada S., Gómez-Llorente C., Gil A. Probiotic mechanisms of action. Ann. Nutr. Metab. 2012, 61:160-174. 10.1159/000342079.
12. Bernardo W.M., Aires F.T., Carneiro R.M., Sá F.P., Rullo V.E., Burns D.A. Effectiveness of probiotics in the prophylaxis of necrotizing enterocolitis in preterm neonates: a systematic review and meta-analysis. J. Pediatr. (Rio J.) 2013, 89:18-24.
13. Bibiloni R., Fedorak R.N., Tannock G.W., Madsen K.L., Gionchetti P., Campieri M., De Simone C., Sartor R.B. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am. J. Gastroenterol. 2005, 100(7):1539-1546.
14. Billoo A.G., Memon M.A., Khaskheli S.A., Murtaza G., Iqbal K., Saeed S.M., Siddiqi A.Q. Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea. World J. Gastroenterol. 2006, 12(28):4557-4560.
15. Bin-Nun A., Bromiker R., Wilschanski M., Kaplan M., Rudensky B., Caplan M., Hammerman C. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J. Pediatr. 2005, 147(2):192-196.
16. Bjorksten B., Naaber P., Sepp E., Mikelsaar M. The intestinal microflora in allergic Estonian and Swedish2-year-old children. Clin. Exp. Allergy 1999, 29:342-346.
17. Bjorksten B., Sepp E., Julge K., Voor T., Mikelsaar M. Allergy development and the intestinal microflora during the first year of life. J. Allergy Clin. Immunol. 2001, 108:516-520.
18. Borges S., Barbosa J., Silva J., Teixeira P. Evaluation of characteristics of Pediococcus spp. to be used as a vaginal probiotic. J. Appl. Microbiol. 2013, 115:527-538.
19. Boudraa G., Benbouabdellah M., Hachelaf W., Boisset M., Desjeux J.F., Touhami M. Effect of feeding yogurt versus milk in children with acute diarrhea and carbohydrate malabsorption. J. Pediatr. Gastroenterol. Nutr. 2001, 33(3):307-313.
20. Boyle R.J., Ismail I.H., Kivivuori S., Licciardi P.V., Robins-Browne R.M., Mah L.J., Axelrad C., Moore S., Donath S., Carlin J.B., Lahtinen S.J., Tang M.L. Lactobacillus GG treatment during pregnancy for the prevention of eczema: a randomized controlled trial. Allergy 2011, 66(4):509-516. Epub 2010 Dec 1. doi:10.1111/j.1398-9995.2010.02507.x.
21. Braegger C., Chmielewska A., Decsi T., Kolacek S., Mihatsch W., Moreno L., Piescik M., Puntis J., Shamir R., Szajewska H., Turck D., van Goudoever J. Supplementation of infant formula with probiotics and/or prebiotics: a systematic review and comment by the ESPGHAN committee on nutrition. J. Pediatr. Gastroenterol. Nutr. 2011, 52:238-250.
22. Braga T.D., da Silva G.A., de Lira P.I., de Carvalho Lima M. Efficacy of Bifidobacterium breve and Lactobacillus casei oral supplementation on necrotizing enterocolitis in very-low-birth-weight preterm infants: a double-blind, randomized, controlled trial. Am. J. Clin. Nutr. 2011, 93(1):81-86. Epub 2010 Oct 27. doi:10.3945/ajcn.2010.29799.
23. Brigidi P., Vitali B., Swennen E., Bazzocchi G., Matteuzzi D. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhoea. Res. Microbiol. 2001, 152(8):735-741.
24. Bron P.A., van Baarlen P., Kleerebezem M. Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. Nat. Rev. Microbiol. 2012, 10:66-78.
25. Buck B.L., Altermann E., Svingerud T., Klaenhammer T.R. Functional analysis of putative adhesion factors in Lactobacillus acidophilus NCNCFM. Appl. Environ. Microbiol. 2005, 71:8344-8351.
26. Cadieux P.A., Burton J., Devillard E., Reid G. Lactobacillus by-products inhibit the growth and virulence of uropathogenic Escherichia coli. J. Physiol. Pharmacol. 2009, 60(Suppl. 6):13-18.
27. Canani R.B., Cirillo P., Terrin G., Cesarano L., Spagnuolo M.I., De Vincenzo A., Albano F., Passariello A., De Marco G., Manguso F., Guarino A. Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. BMJ 2007, 335(7615):340.
28. Candela M., Rampelli S., Turroni S., Severgnini M., Consolandi C., De Bellis G., Masetti R., Ricci G., Pession A., Brigidi P. Unbalance of intestinal microbiota in atopic children. BMC Microbiol. 2012, 12:95.
29. Candela M., Bergmann S., Vici M., Vitali B., Turroni S., Eikmanns B.J., Hammerschmidt S., Brigidi P. Binding of human plasminogen to Bifidobacterium. J. Bacteriol. 2007, 189:5929-5936.
30. Candela M., Biagi E., Centanni M., Turroni S., Vici M., Musiani F., Vitali B., Bergmann S., Hammerschmidt S., Brigidi P. Bifidobacterial enolase, a cell surface receptor for human plasminogen involved in the interaction with the host. Microbiology 2009, 155:3294-3303.
31. Candela M., Centanni M., Fiori J., Biagi E., Turroni S., Orrico C., Bergmann S., Hammerschmidt S., Brigidi P. DnaK from Bifidobacterium animalis subsp. lactis is a surfaceexposed human plasminogen receptor upregulated in response to bile salts. Microbiology 2010, 156:1609-1618.
32. Carroll I.M., Ringel-Kulka T., Siddle J.P., Ringel Y. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol. Motil. 2012, 24(6):521-530. e248, Epub 2012 Feb 20. 10.1111/j. 1365-2982.2012.01891.x.
33. Chapman C.M., Gibson G.R., Rowland I. Health benefits of probiotics: are mixtures more effective than single strains?. Eur. J. Nutr. 2011, 50(1):1e17.
34. Chapman C.M.C., Gibson G.R., Rowland I. In vitro evaluation of single-and multi-strain probiotics: inter-species inhibition between probiotic strains, and inhibition of pathogens. Anaerobe 2012, 18:405e413.
35. Chapman C.M.C., Gibson G.R., Todd S., Rowland I. Comparative in vitro inhibition of urinary tract pathogens by single-and multi-strain probiotics. Eur. J. Nutr. 2013, 52:1669-1677. 10.1007/s00394-013-0501-2.
36. Chenoll E., Casinos B., Bataller E., Astals P., Echevarría J., Iglesias J.R., Balbarie P., Ramón D., Genovés S. Novel probiotic Bifidobacterium bifidum CECT 7366 strain active against the pathogenic bacterium Helicobacter pylori. Appl. Environ. Microbiol. 2011, 77(4):1335-1343. Epub 2010 Dec 17. doi:10.1128/AEM.01820-10.
37. Ciprandi G., Vizzaccaro A., Cirillo I., Tosca M.A. Bacillus clausii exerts immuno-modulatory activity in allergic subjects: a pilot study. Eur. Ann. Allergy Clin. Immunol. 2005, 37:129-134.
38. Coconnier M.H., Bernet M.F., Chauviere G., Servin A.L. Adhering heat-killed human Lactobacillus acidophilus, strain LB, inhibits the process of pathogenicity of diarrhoeagenic bacteria in cultured human intestinal cells. J. Diarrhoeal Dis. Res. 1993, 11:235-242.
39. Collado M.C., Isolauri E., Salminen S. Specific probiotic strains and their combinations counteract adhesion of Enterobacter sakazakii to intestinal mucus. FEMS Microbiol. Lett. 2008, 285(1):58e64.
40. Collado M.C., Meriluoto J., Salminen S. Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus. Lett. Appl. Microbiol. 2007, 45:454-460. PMID: 17897389. 10.1111/j.1472-765X.2007.02212.x.
41. Collins J., van Pijkeren J., Svensson L., Claesson M., Sturme M., Li Y., Cooney J., van Sinderen D., Walker A.W., Parkhill J., Shannon O., O'Toole P. Fibrinogen-binding and platelet-aggregation activities of a Lactobacillus salivarius septicaemia isolate are mediated by a novel fibrinogen-binding protein. Mol. Microbiol. 2012, 85:862-877.
42. Costa Baptista I.P., Accioly E., de Carvalho P.P. Effect of the use of probiotics in the treatment of children with atopic dermatitis; a literature review. Nutr. Hosp. 2013, 28(1):16-26.
43. Cremonini F., Di Caro S., Covino M., Armuzzi A., Gabrielli M., Santarelli L., Nista E.C., Cammarota G., Gasbarrini G., Gasbarrini A. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am. J. Gastroenterol. 2002, 97(11):2744-2749.
44. Crook W.G. The Yeast Connection 1986, Vintage Books, NewYork, p. 434.
45. Cucchiara S., Falconieri P., Di Nardo G., Parcelii M.A., Dito L., Grandinetti A. New therapeutic approach in the management of intestinal disease: probiotics in intestinal disease in paediatric age. Dig. Liver Dis. 2002, 34(Suppl. 2):S44-S47.
46. Cui H.H., Chen C.L., Wang J.D., Yang Y.J., Cun Y., Wu J.B., Liu Y.H., Dan H.L., Jian Y.T., Chen X.Q. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J. Gastroenterol. 2004, 10(10):1521-1525.
47. Czerucka D., Piche T., Rampal P. Review article: yeast as probiotics-Saccharomyces boulardii. Aliment. Pharmacol. Ther. 2007, 26:767-778.
48. Dinleyici E.C., Eren M., Ozen M., Yargic Z.A., Vandenplas Y. Effectiveness and safety of Saccharomyces boulardii for acute infectious diarrhea. Expert Opin. Biol. Ther. 2012, 12(4):395-410. Epub 2012 Feb 16. Review. PMID: 22335323. 10.1517/14712598.2012.664129.
49. Dotterud C.K., Storrø O., Johnsen R., Oien T. Probiotics in pregnant women to prevent allergic disease: a randomized, double-blind trial. Br. J. Dermatol. 2010, 163(3):616-623. Epub 2010 Jun 9. doi:10.1111/j.1365-2133.2010.09889.x.
50. Drago L., Gismondo M.R., Lombardi A., de Haen C., Gozzini L. Inhibition of in vitro growth of enteropathogens by new Lactobacillus isolates of human intestinal origin. FEMS Microbiol. Lett. 1997, 153(2):455e63.
51. D'Souza A.L., Rajkumar C., Cooke J., Bulpitt C.J. Probiotics in prevention of antibiotic associated diarrhea: meta analysis. BMJ 2002, 324:1361.
52. Elazab N., Mendy A., Gasana J., Vieira E.R., Quizon A., Forno E. Probiotic administration in early life, atopy, and asthma: a meta-analysis of clinical trials. Pediatrics 2013, 132:e666. originally published online August 19, 2013.
53. Elmer G.W., McFarland L.V. Biotherapeutic agents in the treatment of infectious diarrhea. Gastroenterol. Clin. North Am. 2001, 30:837-854.
54. Fabia R., Ar'Rajab A., Johansson M.L., Willen R., Andersson R., Molin G., Bengmark S. The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fiber on acetic acidinduced colitis in the rat. Scand. J. Gastroenterol. 1993, 28(2):155-162.
55. FAO/WHO, 2001. (accessed 28.04.07). http://www.fao.org/es/ESN/probio/probio.htm.
56. Favier C., Neut C., Mizon C., Cortot A., Colombel J.F., Mizon J. Fecal beta-d-galactosidase production and Bifidobacteria are decreased in Crohn's disease. Dig. Dis. Sci. 1997, 42(4):817-822.
57. Fernandez M., Valenti V., Rockel C., Hermann C., Pot B., Boneca I.G., Grangette C. Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide. Gut 2011, 60:1050-1059.
58. Fiocchi A., Burks W., Bahna S.L., Bielory L., Boyle R.J., Cocco R., Dreborg S., Goodman R., Kuitunen M., Haahtela T., Heine R.G., Lack G., Osborn D.A., Sampson H., Tannock G.W., Lee B.W. Clinical use of probiotics in pediatric allergy (CUPPA): a world allergy organization position paper. WAO J. 2012, 5:148-167. On behalf of the WAO Special Committee on Food Allergy and Nutrition.
59. Floch M.H., Walker W.A., Madsen K., Sanders M.E., Macfarlane G.T., Flint H.J., Dieleman L.A., Ringel Y., Guandalini S., Kelly C.P., Brandt L.J. Recommendations for probiotic use-2011 update. J. Clin. Gastroenterol. 2011, 45(3):S168-S171.
60. Forsythe P., Inman M.D., Bienenstock J. Oral treatment with live Lactobacillus reuteri inhibits the allergic airway response in mice. Am. J. Respir. Crit. Care Med. 2007, 175:561-569.
61. Fujiwara S., Hashiba H., Hirota T., Forstner J.F. Inhibition of the binding of enterotoxigenic Escherichia coli Pb176 to human intestinal epithelial cell line HCT-8 by an extracellular protein fraction containing BIF of Bifidobacterium longum SBT2928: suggestive evidence of blocking of the binding receptor gangliotetraosylceramide on the cell surface. Int. J. Food Microbiol. 2001, 67:97-106.
62. Fuller R. Probiotics in man and animals. J. Appl. Bacteriol. 1989, 66:365.
63. Furrie E., Macfarlane S., Kennedy A., Cummings J.H., Walsh S.V., O'neil D.A., Macfarlane G.T. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 2005, 54:242-249.
64. Gionchetti P., Rizzello F., Helwig U., Venturi A., Lammers K.M., Brigidi P., Vitali B., Poggioli G., Miglioli M., Campieri M. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebocontrolled trial. Gastroenterology 2003, 124(5):1202-1209.
65. Goh Y.J., Klaenhammer T.R. Functional roles of aggregation-promoting-like factor in stress tolerance and adherence of Lactobacillus acidophilus NCFM. Appl. Environ. Microbiol. 2010, 76:5005-5012.
66. Gómez-Llorente C., Muñoz S., Gil A. Role of Toll-like receptors in the development of immunotolerance mediated by probiotics. Proc. Nutr. Soc. 2010, 69:381-389.
67. Grandy G., Medina M., Soria R., Terán C.G., Araya M. Probiotics in the treatment of acute rotavirus diarrhoea. A randomized, double-blind, controlled trial using two different probiotic preparations in Bolivian children. BMC Infect. Dis. 2010, 10:253.
68. Gronlund M.M., Lehtonen O.P., Eerola E., Kero P. Faecal microflora in healthy infants born by different methods of delivery: permanent changes in intestinal flora after cesarean delivery. J. Pediatr. Gastroenterol. Nutr. 1999, 28:19-25.
69. Grzeskowiak L., Gronlund M.M., Beckmann C., Salminen S., von Berg A., Isolauri E. The impact of perinatal probiotic intervention on gut microbiota: double-blind placebo-controlled trials in Finland and Germany. Anaerobe 2012, 18:7-13.
70. Gueimonde M., Collado M.C. Metagenomics and probiotics. Clin. Microbiol. Infect. 2012, 18(Suppl. 4):32-34.
71. Guenther K., Straube E., Pfister W., Guenther A., Huebler A. Severe sepsis after probiotic treatment with Escherichia coli NISSLE 1917. Pediatr. Infect. Dis. J. 2010, 29:188-189.
72. Guglielmetti S., Tamagnini I., Mora D., Minuzzo M., Scarafoni A., Arioli S., Hellman J., Karp M., Parini C. Implication of an outer surface lipoprotein in adhesion of Bifidobacterium bifidum to Caco-2 cells. Appl. Environ. Microbiol. 2008, 74:4695-4702.
73. Hakansson A., Molin G. Gut microbiota and inflammation. Nutrients 2011, 3:637-682.
74. Haller D., Antoine J.M., Bengmark S., Enck P., Rijkers G.T., Lenoir-Wijnkoop I. Guidance for substantiating the evidence for beneficial effects of probiotics: probiotics in chronic inflammatory bowel disease and the functional disorder irritable bowel syndrome. J. Nutr. 2010, 140(3):690S-697S.
75. Haller D., Colbus H., Ganzle M.G., Scherenbacher P., Bode C., Hammes W.P. Metabolic and functional properties of lactic acid bacteria in the gastro-intestinal ecosystem: a comparative in vitro study between bacteria of intestinal and fermented food origin. Syst. Appl. Microbiol. 2001, 24:218-226.
76. Harmsen H.J., Wildeboer-Veloo A.C., Raangs G.C., Wagendorp A.A., Klijn N., Bindels J.G., Welling G.W. Analysis of intestinal flora development in breast-fed and formula-fed infants by using molecular identification and detection methods. J. Pediatr. Gastroenterol. Nutr. 2000, 30:61-67.
77. Hickson M. Examining the evidence for the use of probiotics in clinical practice. Nurs. Stand. 2013, 27(29):35-41.
78. Hirano J., Yoshida T., Sugiyama T., Koide N., Mori I., Yokochi T. The effect of Lactobacillus rhamnosus on enterohemorrhagic Escherichia coli infection of human intestinal cells in vitro. Microbiol. Immunol. 2003, 47:405-409.
79. Holzapfel W.H., Haberer P., Snel J., Schillinger U., Huis in't Veld J.H. Overview of gut flora and probiotics. Int. J. Food Microbiol. 1998, 41:85-101.
80. Hooper L.V., Wong M.H., Thelin A., Hansson L., Falk P.G., Gordon J.I. Molecular analysis of commensal host-microbial relationships in the intestine. Science 2001, 291:881-884.
81. Hougee S., Vriesema A.J., Wijering S.C., Knippels L.M., Folkerts G., Nijkamp F.P., Knol J., Garssen J. Oral treatment with probiotics reduces allergic symptoms in ovalbumin-sensitized mice: a bacterial strain comparative study. Int. Arch. Allergy Immunol. 2010, 151:107-117.
82. Howden E.J., Leano R., Petchey W., Coombes J.S., Isbel N.M., Marwick T.H. Effects of exercise and lifestyle intervention on cardiovascular function in CKD. Clin. J. Am. Soc. Nephrol. 2013, 8:1494-1501.
83. Htwe K., Yee K.S., Tin M., Vandenplas Y. Effect of Saccharomyces boulardii in the treatment of acute watery diarrhea in Myanmar children: a randomized controlled study. Am. J. Trop. Med. Hyg. 2008, 78(2):214-216.
84. Hummel S., Veltman K., Cichon C., Sonnenborn U., Schmidt M.A. Differential targeting of the E-cadherin/_-catenin complex by Gram-positive probiotic lactobacilli improves epithelial barrier function. Appl. Environ. Microbiol. 2012, 78:1140-1147.
85. Hungin A.P.S., Mulligan C., Pot B., Whorwell P., Agrèus L., Fracasso P., Lionis C., Mendive J., Philippart de Foy J.-M., Rubin G., Winchester C., de Wit N. Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice-an evidence based international guide. Aliment. Pharmacol. Ther. 2013, 38:864-886.
86. Huurre A., Laitinen K., Rautava S., Korkeamäki M., Isolauri E. Impact of maternal atopy and probiotic supplementation during pregnancy on infant sensitization: a double-blind placebo-controlled study. Clin. Exp. Allergy 2008, 38(8):1342-1348. Epub 2008 May 8. doi:10.1111/j.1365-2222.2008.03008.x.
87. Hutt P., Shchepetova J., Loivukene K., Kullisaar T., Mikelsaar M. Antagonistic activity of probiotic lactobacilli and bifidobacteria against entero-and uropathogens. J. Appl. Microbiol. 2006, 100(6):1324e32.
88. Hynönen U., Westerlund-Wikström B., Palva A., Korhonen T.K. Identification by flagellum display of an epithelial cell and fibronectin binding function in the SlpA surface protein of Lactobacillus brevis. J. Bacteriol. 2002, 184:3360-3367.
89. Iniesta M., Herrera D., Montero E., Zurbriggen M., Matos A.R., Marìn M.J., Sànchez-Beltràn M.C., Llama-Palacio A., Sanz M. Probiotic effects of orally administered Lactobacillus reuteri-containing tablets on the subgingival and salivary microbiota in patients with gingivitis. A randomized clinical trial. J. Clin. Periodontol. 2012, 39:736-744.
90. Ismail I.H., Licciardi P.V., Tang M.L.K. Probiotic effects in allergic disease. J. Paediatr. Child Health 2013, 49:709-715.
91. Isolauri E., Kaila M., Mykkanen H., Ling W.H., Salminen S. Oral bacteriotherapy for viral gastroenteritis. Dig. Dis. Sci. 1994, 39:2595-2600.
92. Johansson M.A., Sjogren Y.M., Persson J.O., Nilsson C., Sverremark-Ekstrom E. Early colonization with a group of Lactobacilli decreases the risk for allergy at five years of age despite allergic heredity. PLoS One 2011, 6. e23031. 10.1371/journal.pone.0023031.
93. Johnston B.C., Goldenberg J.Z., Vandvik P.O., Sun X., Guyatt G.H. Probiotics for the prevention of pediatric antibiotic associated diarrhea. Cochrane Database Syst. Rev. 2011, 11. CD004827.
94. Juntunen M., Kirjavainen P.V., Ouwehand A.C., Salminen S.J., Isolauri E. Adherence of probiotic bacteria to human intestinal mucus in healthy infants and during rotavirus infection. Clin. Diagn. Lab. Immunol. 2001, 8:293-296.
95. Kajander K., Hatakka K., Poussa T., Färkkilä M., Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6 month intervention. Aliment. Pharmacol. Ther. 2005, 22:387-394.
96. Kajander K., Krogius-Kurikka L., Rinttila T., Karjalainen H., Palva A., Korpela R. Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome. Aliment. Pharmacol. Ther. 2007, 26(3):463-473.
97. Kajander K., Myllyluoma E., Rajilic-Stojanovic M., Kyronpalo S., Rasmussen M., Jarvenpaa S., Zoetendal E.G., de Vos W.M., Vapaatalo H., Korpela R. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment. Pharmacol. Ther. 2008, 27(1):48-57.
98. Kalliomaki M., Kirjavainen P., Eerola E., Kero P., Salminen S., Isolauri E. Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J. Allergy Clin. Immunol. 2001, 107:129-134.
99. Kanauchi O., Matsumoto Y., Matsumura M., Fukuoka M., Bamba T. The beneficial effects of microflora, especially obligate anaerobes, and their products on the colonic environment in inflammatory bowel disease. Curr. Pharm. Des. 2005, 11:1047-1053. PMID: 15777254. 10.2174/1381612053381675.
100. Kankainen M., Paulin L., Tynkkynen S., von Ossowski I., Reunanen J., Partanen P., Satokari R., Vesterlund S., Hendrickx A.P., Lebeer S., De Keersmaecker S.C., Vanderleyden J., Hämäläinen T., Laukkanen S., Salovuori N., Ritari J., Alatalo E., Korpela R., Mattila-Sandholm T., Lassig A., Hatakka K., Kinnunen K.T., Karjalainen H., Saxelin M., Laakso K., Surakka A., Palva A., Salusjärvi T., Auvinen P., de Vos W.M. Comparative genomic analysis of Lactobacillus rhamnosus GG reveals pili containing a human-mucus binding protein. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:17193-17198.
101. Karimi K., Inman M.D., Bienenstock J., Forsythe P. Lactobacillus reuteriinduced regulatory T cells protect against an allergic airway response in mice. Am. J. Respir. Crit. Care Med. 2009, 179:186-193.
102. Kim H.J., Camilleri M., McKinzie S., Lempke M.B., Burton D.D., Thomforde G.M., Zinsmeister A.R. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 2003, 17(7):895-904.
103. Kim H.J., Vazquez Roque M.I., Camilleri M., Stephens D., Burton D.D., Baxter K., Thomforde G., Zinsmeister A.R. A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol. Motil. 2005, 17(5):687-696.
104. Kim Y., Kim S.H., Whang K.Y., Kim Y.J., Oh S. Inhibition of Escherichia coli O157:H7 attachment by interactions between lactic acid bacteria and intestinal epithelial cells. J. Microbiol. Biotechnol. 2008, 18:1278-1285.
105. Kim Y.S., Ho S.B. Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr. Gastroenterol. Rep. 2010, 12:319-330.
106. Kim J.Y., Kwon J.H., Ahn S.H., Lee S.I., Han Y.S., Choi Y.O., Lee S.Y., Ahn K.M., Ji G.E. Effect of probiotic mix (Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus) in the primary prevention of eczema: a double-blind, randomized, placebo-controlled trial. Pediatr. Allergy Immunol. 2010, 21(2 Pt 2):e386-e393. Epub 2009 Oct 14. doi:10.1111/j.1399-3038.2009.00958.x.
107. Kleessen B., Bezirtzoglou E., Matto J. Culture-based knowledge on biodiversity, development and stability of human gastrointestinal microflora. Microb. Ecol. Health Dis. 2000, 12:53-63.
108. Koll P., Mandar R., Marcotte H., Leibur E., Mikelsaar M., Hammarstrom L. Characterization of oral lactobacilli as potential probiotics for oral health. Oral Microbiol. Immunol. 2008, 23(2):139e47.
109. Kotzampassi K., Giamarellos-Bourboulis E.J. Probiotics for infectious diseases: more drugs, less dietary supplementation. Int. J. Antimicrob. Agents 2012, 40:288-296. PMID: 22858373. 10.1016/j.ijantimicag.2012.06.006.
110. Kuitunen M., Kukkonen K., Juntunen-Backman K., Korpela R., Poussa T., Tuure T., Haahtela T., Savilahti E. Probiotics prevent IgE-associated allergy until age 5 years in cesarean-delivered children but not in the total cohort. J. Allergy Clin. Immunol. 2009, 123(2):335-3341. Epub 2009 Jan 8. doi:10.1016/j.jaci.2008.11.019.
111. Kukkonen K., Savilahti E., Haahtela T., Juntunen-Backman K., Korpela R., Poussa T., Tuure T., Kuitunen M. Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. J. Allergy Clin. Immunol. 2007, 119(1):192-198. Epub 2006 Oct 23.
112. Kulp W.L., Rettger L.F. Comparative study of Lactobacillus acidophilus and Lactobacillus bulgaricus. J. Bacteriol. 1924, 9:357-395.
113. Kurugol Z., Koturoglu G. Effects of Saccharomyces boulardii in children with acute diarrhoea. Acta Paediatr. 2005, 94(1):44-47.
114. Lahtinen S.J., Boyle R.J., Kivivuori S., Oppedisano F., Smith K.R., Robins-Browne R., Salminen S.J., Tang M.L. Prenatal probiotic administration can infl uence Bifidobacterium microbiota development in infants at high risk of allergy. J. Allergy Clin. Immunol. 2009, 123:499-501.
115. Land M.H., Rouster-Stevens K., Woods C.R., Cannon M.L., Cnota J., Shetty A.K. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005, 115:178-181.
116. Le Chatelier E., Nielsen T., Qin J., Prifti E., Hildebrand F., Falony G., Almeida M., Arumugam M., Batto J.M., Kennedy S., Leonard P., Li J., Burgdorf K., Grarup N., Jørgensen T., Brandslund I., Nielsen H.B., Juncker A.S., Bertalan M., Levenez F., Pons N., Rasmussen S., Sunagawa S., Tap J., Tims S., Zoetendal E.G., Brunak S., Clément K., Doré J., Kleerebezem M., Kristiansen K., Renault P., Sicheritz-Ponten T., de Vos W.M., Zucker J.D., Raes J., Hansen T., MetaHIT consortium, Bork P., Wang J., Ehrlich S.D., Pedersen O. Richness of human gut microbiome correlates with metabolic markers. Nature 2013, 500(7464):541-546. 10.1038/nature12506.
117. Leach J. Gut microbiota: please pass the microbes. Nature 2013, 504(7478):33. 10.1038/504033c.
118. Leahy S.C., Higgins D.G., Fitzgerald G.F., van Sinderen D. Getting better with bifidobacteria. J. Appl. Microbiol. 2005, 98:1303-1315.
119. Lebeer S., Vanderleyden J., De Keersmaecker C.J. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat. Rev. Microbiol. 2010, 8:171-184.
120. Lee M.C., Lin L.H., Hung K.L., Wu H.Y. Oral bacterial therapy promotes recovery from acute diarrhea in children. Acta Paediatr. Taiwan. 2001, 42:301-305.
121. Lilly D.M., Stillwell R.H. Probiotics: growth-promoting factors produced by microorganisms. Science 1965, 147:747.
122. Lin T.Y., Hung T.H., Cheng T.-S.J. Conjugated linoleic acid production by immobilized cells of Lactobacillus delbrueckii ssp. bulgaricus and Lactobacillus acidophilus. Food Chem. 2005, 92:23-28.
123. Lin H.C., Hsu C.H., Chen H.L., Chung M.Y., Hsu J.F., Lien R.I., Tsao L.Y., Chen C.H., Su B.H. Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial. Pediatrics 2008, 122(4):693-700. doi:10.1542/peds.2007-3007.
124. Lin J.S., Chiu Y.H., Lin N.T., Chu C.H., Huang K.C., Liao K.W., Peng K.C. Different effects of probiotic species/strains on infections in preschool children: a double-blind, randomized, controlled study. Vaccine 2009, 27(7):1073e9.
125. Lyons A., O'Mahony D., O'Brien F., MacSherry J., Sheil B., Ceddia M., Russell W.M., Forsythe P., Bienenstock J., Kiely B., Shanahan F., O'Mahony L. Bacterial strain-specific induction of Foxp3 T regulatory cells is protective in murine allergy models. Clin. Exp. Allergy 2010, 40:811-819.
126. Lyra A., Krogius-Kurikka L., Nikkilä J., Malinen E., Kajander K., Kurikka K., Korpela R., Palva A. Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes. BMC Gastroenterol. 2010, 10:110.
127. Macho Fernandez E., Pot B., Grangette C. Beneficial effect of probiotics in IBD: are peptidogycan and NOD2 the molecular key effectors?. Gut Microbes 2011, 2:280-286. PMID: 22067939. 10.4161/gmic.2.5.18255.
128. Mack D.R. Probiotics in inflammatory bowel diseases and associated conditions. Nutrients 2011, 3:245-264. PMID:22254095. 10.3390/nu3020245.
129. Mack D.R., Ahrne S., Hyde L., Wei S., Hollingsworth M.A. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut 2003, 52:827-833.
130. Mack D.R., Lebel S. Role of probiotics in the modulation of intestinal infections and inflammation. Curr. Opin. Gastroenterol. 2004, 20:22-26.
131. Mack D.R., Michail S., Wei S., McDougall L., Hollingsworth M.A. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am. J. Physiol. 1999, 276:941-950.
132. Mackowiak P.A. Recycling Metchnikoff: probiotics, the intestinal microbiome and the quest for long life. Front. Public Health 2013, 1:52. 10.3389/fpubh.2013.00052.
133. Mallon P., McKay D., Kirk S., Gardiner K. Probiotics forinduction of remission in ulcerative colitis. Cochrane Database Syst. Rev. 2007, ((4),). Article ID: CD005573.
134. Mao Y., Nobaek S., Kasravi B., Adawi D., Stenram U., Molin G., Jeppsson B. The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats. Gastroenterology 1996, 111:334-344.
135. Marseglia G.L., Tosca M., Cirillo I., Licari A., Leone M., Marseglia A., Castellazzi A.M., Ciprandi G. Efficacy of Bacillus clausii spores in the prevention of recurrent respiratory infections in children: a pilot study. Ther. Clin. Risk Manag. 2007, 3:13-17.
136. Marteau P. Factors controlling the bacterial microflora. Definitions and mechanisms of action of probiotics and prebiotics. Gut Microflora, 2006, 37-58.
137. Martin R., Langa S., Reviriego C., Jimìnez E., Marìn M.L., Xaus J., Fernàndez L., Rodrìguez J.M. Human milk is a source of lactic acid bacteria for the infant gut. J. Pediatr. 2003, 143:754-758.
138. Mathur S., Singh R. Antibiotic resistance in food lactic acid bacteria-a review. Int. J. Food Microbiol. 2005, 105:281-295.
139. Mattar A.F., Teitelbaum D.H., Drongowski R.A., Yongyi F., Harmon C.M., Coran A.G. Probiotics up-regulate MUC-2 mucin gene expression in a Caco-2 cell-culture model. Pediatr. Surg. Int. 2002, 18:586-590.
140. McFarland L.V. Normal flora: diversity and functions. Microb. Ecol. Health Dis. 2000, 12:193-207.
141. McFarland L.V. Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review. BMJ Open 2014, 4. e005047. 10.1136/bmjopen-2014-005047.
142. Mcfarlane G.T., Cummings J.H. Probiotics and prebiotics: can regulating the activities of intestinal bacteria benefit health?. BMJ 1999, 318:999-1003.
143. McNulty N.P., Yatsunenko T., Hsiao A., Faith J.J., Muegge B.D., Goodman A.L., Henrissat B., Oozeer R., Cools-Portier S., Gobert G., Chervaux C., Knights D., Lozupone C.A., Knight R., Duncan A.E., Bain J.R., Muehlbauer M.J., Newgard C.B., Heath A.C., Gordon J.I. The impact of a consortium of fermented milk strains on the gut microbiome of gnotobiotic mice and monozygotic twins. Sci. Transl. Med. 2011, 3:106ra106.
144. Mehal W.Z. The gordian knot of dysbiosis, obesity and NAFLD. Nat. Rev. Gastroenterol. Hepatol. 2013, 10(11):637-644.
145. Mercenier A., Pavan S., Pot B. Probiotics as biotherapeutic agents: present knowledge and future prospects. Curr. Pharm. Des. 2003, 9:175-191.
146. Metchnikoff E. The Prolongation of Life. Optimistic Studies 1910, 96. G P Putnam's Sons, New York. P.C. Mitchell (Ed.).
147. Miele E., Pascarella F., Giannetti E., Quaglietta L., Baldassano R.N., Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am. J. Gastroenterol. 2009, 104:437-443.
148. Mimura T., Rizzello F., Helwig U., Poggioli G., Schreiber S., Talbot I.C., Nicholls R.J., Gionchetti P., Campieri M., Kamm M.A. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004, 53(1):108-114.
149. Mitterdorfer G., Mayer H.K., Kneifel W., Vierstain H. Clustering of Saccharomyces boulardii strains within the species S. cerevisiae using molecular typing techniques. J. Appl. Microbiol. 2002, 93:521-530.
150. Mohseni M.-J., Aryan Z., Emamzadeh-Fard S., Paydary K., Mofid V., Joudaki H., Kajbafzadeh A.-M. Combination of probiotics and antibiotics in the prevention of recurrent urinary tract infection in children. Iran. J. Pediatr. 2013, 23(4):430-438.
151. Mukai T., Asasaka T., Sato E., Mori K., Matsumoto M., Ohori H. Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol. Med. Microbiol. 2002, 32:105-110.
152. Myllyluoma E., Veijola L., Ahlroos T., Tynkkynen S., Kankuri E., Vapaatalo H., Rautelin H., Korpela R. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy-a placebo-controlled, double-blind randomized pilot study. Aliment. Pharmacol. Ther. 2005, 21(10):1263-1272.
153. Naderi A., Kasra-Kermanshahi R., Gharavi S., Imani Fooladi A.A., Abdollahpour A.M., Saffarian P. Study of antagonistic effects of Lactobacillus strains as probiotics on multi drug resistant bacteria isolated from urinary tract infections. Iran. J. Basic Med. Sci. 2014, 17:201-208.
154. Nesser J.R., Granato D., Rouvet M., Servin A., Teneberg S., Karlsson K.A. Lactobacillus johnsonii La1 shares carbohydrate-binding specificities with several enteropathogenic bacteria. Glycobiology 2000, 10:1193-1199.
155. Niers L., Martín R., Rijkers G., Sengers F., Timmerman H., van Uden N., Smidt H., Kimpen J., Hoekstra M. The effects of selected probiotic strains on the development of eczema (the PandA study). Allergy 2009, 64(9):1349-1358. Epub 2009 Apr 9. doi:10.1111/j.1398-9995.2009.02021.x.
156. Nugent R.P., Krohn M.A., Hillier S.L. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J. Clin. Microbiol. 1991, 29:297-301.
157. Nylund L., Satokari R., Nikkilä J., Rajilić-Stojanović M., Kalliomäki M., Isolauri E., Salminem S., de Vos W.M. Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease. BMC Microbiol. 2013, 13:12.
158. O'Sullivan M.A., O'Morain C.A. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig. Liver Dis. 2000, 32(4):294-301.
159. Ohishi A., Takahashi S., Ito Y., Ohishi Y., Tsukamoto K., Nanba Y., Ito N., Kakiuchi S., Saitoh A., Morotomi M., Nakamura T. Bifidobacterium septicemia associated with postoperative probiotic therapy in a neonate with omphalocele. J. Pediatr. 2010, 156:679-681.
160. Olivares M., Diaz-Ropero M.A., Gomez N., Lara-Villoslada F., Sierra S., Maldonado J.A., Martin R., Lopez-Huertas E., Rodriguez J.M., Xaus J. Oral administration of two probiotic strains, Lactobacillus gasseri CECT5714 and Lactobacillus coryniformis CECT5711, enhances the intestinal function of healthy adults. Int. J. Food Microbiol. 2006, 107(2):104-111.
161. Orel R., Kamhi T.T. Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease. World J. Gastroenterol. 2014, 20(33):11505-11524.
162. Otte J.M., Podolsky D.K. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 286:G613-G626.
163. Ou C.Y., Kuo H.C., Wang L., Hsu T.Y., Chuang H., Liu C.A., Chang J.C., Yu H.R., Yang K.D. Prenatal and postnatal probiotics reduces maternal but not childhood allergic diseases: a randomized, double-blind, placebo-controlled trial. Clin. Exp. Allergy 2012, 42(9):1386-1396. doi:10.1111/j.1365-2222.2012.04037.x.
164. Ouwehand A.C. Antimicrobial components from lactic acid bacteria. Lactic Acid Bacteria: Microbiology and Functional Aspects 1998, 139-159. Dekker, New York. S. Salminen, A. von Wright (Eds.).
165. Ouwehand A.C., Lagstrom H., Suomalainen T., Salminen S. Effect of probiotics on constipation, fecal azoreductase activity and fecal mucin content in the elderly. Ann. Nutr. Metab. 2002, 46(3-4):159-162.
166. Ouwehand A.C., Salminen S., Tolkko S., Roberts P., Ovaska J., Salminen E. Resected human colonic tissue: new model for characterizing adhesion of lactic acid bacteria. Clin. Diagn. Lab. Immunol. 2002, 9:184-186.
167. Parassol N., Freitas M., Thoreux K., Dalmasso G., Bourdet-Sicard R., Rampal P. Lactobacillus casei DN-114001 inhibits the increase in paracellular permeability of enteropathogenic Escherichia coli-infected T84 cells. Res. Microbiol. 2005, 156:256-262.
168. Park K.T., Perez F., Tsai R., Honkanen A., Bass D., Garber A. Cost-effectiveness analysis of adjunct VSL#3 therapy versus standard medical therapy in pediatric ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. 2011, 53:489-496.
169. Parker R.B. Anim. Nutr. Health 1989, 29:4.
170. Patel R.M., Denning P.W. Therapeutic use of prebiotics, probiotics, and postbiotics to prevent necrotizing enterocolitis: what is the current evidence?. Clin. Perinatol. 2013, 40(1):11-25. 10.1016/j.clp.2012.12.002.
171. Patel S.M., Stason W.B., Legedza A., Ock S.M., Kaptchuk T.J., Conboy L., Canenguez K., Park J.K., Kelly E., Jacobson E., Kerr C.E., Lembo A.J. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol. Motil. 2005, 17(3):332-340.
172. Perdigon G., Maldonado G.C., Valdez J.C., Medici M. Interaction of lactic acid bacteria with the gut immune system. Eur. J. Clin. Nutr. 2002, 56:S21-S26.
173. Pham M., Lemberg D.A., Day A.S. Probiotics: sorting the evidence from the myths. Med. J. Aust. 2008, 188(5):304-308.
174. Pothoulakis C., Kelly C.P., Joshi M.A., Gao N., O'Keane C.J., Castagliuolo I., Lamont J.T. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 1993, 104:1108-1115.
175. Prince T., McBain A.J., O'Neill C.A. Lactobacillus reuteri protects epidermal keratinocytes from Staphylococcus aureus-induced cell death by competitive exclusion. Appl. Environ. Microbiol. 2012, 78:5119-5126.
176. Prisciandaro L., Geier M., Butler R., Cummins A., Howarth G. Probiotics and their derivatives as treatments for inflammatory bowel disease. Inflamm. Bowel Dis. 2009, 15:1906-1914. PMID: 19373788. 10.1002/ibd.20938.
177. Quak S.H. Role of probiotics and nutrition in the management of chronic inflammatory bowel disease in children. Singapore Med. J. 2013, 54(4):183-184. 10.11622/smedj.2013069.
178. QuanToh Z., Anzela A., Tang M.L.K., Licciardi P.V. Probiotic therapy as a novel approach for allergic disease. Front. Pharmacol. 2012, 3:1-14. 10.3389/fphar.2012.00171.
179. Rautava S., Kainonen E., Salminen S., Isolauri E. Maternal probiotic supplementation during pregnancy and breast-feeding reduces the risk of eczema in the infant. J. Allergy Clin. Immunol. 2012, 130(6):1355-1360. Epub 2012 Oct 16. doi:10.1016/j.jaci.2012.09.003.
180. Reid G., Chan R.C., Bruce A.W., Costerton J.W. Prevention of urinary tract infection in rats with an indigenous Lactobacillus casei strain. Infect. Immun. 1985, 49(2):320-324.
181. Reid G., Jass J., Sebulsky M.T., McCormick J.K. Potential use of probiotics in clinical practice. Clin. Microbiol. Rev. 2003, 16:658-672.
182. Ridwan B.U., Koning C.J., Besselink M.G., Timmerman H.M., Brouwer E.C., Verhoef J., Gooszen H.G., Akkermans L.M. Antimicrobial activity of a multispecies probiotic (Ecologic 641) against pathogens isolated from infected pancreatic necrosis. Lett. Appl. Microbiol. 2008, 46(1):61e7.
183. Rougé C., Piloquet H., Butel M.J., Berger B., Rochat F., Ferraris L., Des Robert C., Legrand A., de la Cochetière M.F., N'Guyen J.M., Vodovar M., Voyer M., Darmaun D., Rozé J.C. Oral supplementation with probiotics in very-low-birth-weight preterm infants: a randomized, double-blind, placebo-controlled trial. Am. J. Clin. Nutr. 2009, 89(6):1828-1835. Epub 2009 Apr 15. doi:10.3945/ajcn.2008.26919.
184. Russell J.B., Diez-Gonzalez F. The effects of fermentation acids on bacterial growth. Adv. Microb. Physiol. 1998, 39:205-234.
185. Salminen S., von Wright A., Morelli L., Marteau P., Brassart D., de Vos W.M., Fonden R., Saxelin M., Collins K., Mogensen G., Birkeland S.E., Mattila-Sandholm T. Int. J. Food Microbiol. 1998, 44:93.
186. Samanta M., Sarkar M., Ghosh P., Ghosh J.K., Sinha M.K., Chatterjee S. Prophylactic probiotics for prevention of necrotizing enterocolitis in very low birth weight newborns. J. Trop. Pediatr. 2009, 55(2):128-131. Epub 2008 Oct 8. doi:10.1093/tropej/fmn091.
187. Sánchez B., González-Tejedo C., Ruas-Madiedo P., Urdaci M.C., Margolles A. Lactobacillus plantarum extracellular chitin-binding protein and its role in the interaction between chitin, Caco-2 cells, and mucin. Appl. Environ. Microbiol. 2011, 77:1123-1126.
188. Sánchez B., Urdaci M.C., Margolles A. Extracellular proteins secreted by probiotic bacteria as mediators of effects that promote mucosa-bacteria interactions. Microbiology 2010, 156:3232-3242.
189. Sanders M.E. Impact of probiotics on colonizing microbiota of the gut. J. Clin. Gasteroenterol. 2011, 45:S115-S119.
190. Sartor R.B. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004, 126:1620-1633.
191. Sartor R.B. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008, 134:577-594.
192. Schiffrin E.J., Blum S. Interactions between the microbiota and the intestinal mucosa. Eur. J. Clin. Nutr. 2002, 56:S60-S64.
193. Schiffrin E.J., Brassart D., Servin A.L., Rochat F., Donnet-Hughes A. Immune modulation of blood leukocytes in humans by lactic acid bacteria: criteria for strain selection. Am. J. Clin. Nutr. 1997, 66:515S-520S.
194. Schmeisser C., Steele H., Streit W.R. Metagenomics, biotechnology with non-culturable microbes. Appl. Microbiol. Biotechnol. 2007, 75:955-962.
195. Shah M.P., Gujjari S.K., Chandrasekhar V.S. Evaluation of the effect of probiotic (inersan) alone, combination of probiotic with doxycycline and doxycycline alone on aggressive periodontitis-a clinical and microbiological study. J. Clin. Diagn. Res. 2013, 7:595-600.
196. Shimizu K., Ogura H., Asahara T., Nomoto K., Morotomi M., Tasaki O., Matsushima A., Kuwagata Y., Shimazu T., Sugimoto H. Probiotic/synbiotic therapy for treating critically ill patients from a gut microbiota perspective. Dig. Dis. Sci. 2013, 58:23-32. 10.1007/s10620-012-2334-x.
197. Shimizu K., Ogura H., Goto M., Asahara T., Nomoto K., Morotomi M., Matsushima A., Tasaki O., Fujita K., Hosotsubo H., Kuwagata Y., Tanaka H., Shimazu T., Sugimoto H. Synbiotics decrease the incidence of septic complications in patients with severe SIRS: a preliminary report. Dig. Dis. Sci. 2009, 54:1071-1078.
198. Soh S.E., Aw M., Gerez I., Chong Y.S., Rauff M., Ng Y.P., Wong H.B., Pai N., Lee B.W., Shek L.P. Probiotic supplementation in the first 6 months of life in at risk Asian infants-effects on eczema and atopic sensitization at the age of 1 year. Clin. Exp. Allergy 2009, 39(4):571-578. Epub 2008 Dec 9. doi:10.1111/j.1365-2222.2008.03133.x.
199. Solis G., de Los Reyes-Gavilan C.G., Fernandez N., Margolles A., Gueimonde M. Establishment and development of lactic acid bacteria and bifi dobacteria microbiota in breast-milk and the infant gut. Anaerobe 2010, 16:307-310.
200. Strachan D.P. Hay fever, hygiene, and household size. BMJ 1989, 299(6710):1259-1260.
201. Stephani J., Radulovic K., Niess J.H. Gut microbiota, probiotics and inflammatory bowel disease. Arch. Immunol. Ther. Exp. (Warsz.) 2011, 59:161-177. PMID: 21445715. 10.1007/s00005-011-0122-5.
202. Stetinova V., Smetanova L., Kvetina J., Svoboda Z., Zidek Z., Tlaskalova-Hogenova H. Caco-2 cell monolayer integrity and effect of probiotic Escherichia coli Nissle 1917 components. Neuro Endocrinol. Lett. 2010, 31:51-56.
203. Suvorov A. Gut microbiota, probiotics, and human health. Biosci. Microbiota Food Health 2013, 32(3):81-91.
204. Szajewska H., Kotowska M., Murkowicz J.Z., Armanska M., Mikolajczyk W. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. J. Pediatr. 2001, 138:361-365.
205. Szymanski H., Pejcz J., Jawien M., Chmielarczyk A., Strus M., Heczko P.B. Treatment of acute infectious diarrhoea in infants and children with a mixture of three Lactobacillus rhamnosus strains-a randomized, double blind, placebo-controlled trial. Aliment. Pharmacol. Ther. 2006, 23(2):247-253.
206. Teitelbaum J.E., Walker W.A. Nutritional impact of pre-and probiotics as protective gastrointestinal organisms. Annu. Rev. Nutr. 2002, 22:107-138.
207. Teughels W., Durukan A., Ozcelik O., Pauwels M., Quirynen M., Haytac M.C. Clinical and microbiological effects of Lactobacillus reuteri probiotics in the treatment of chronic periodontitis: a randomized placebo-controlled study. J. Clin. Periodontol. 2013, 40:1025-1035.
208. Thomas D.W., Greer F.R. Probiotics and prebiotics in pediatrics. Pediatrics 2010, 126:1217-1231.
209. Timmerman H.M., Koning C.J., Mulder L., Rombouts F.M., Beynen A.C. Monostrain, multistrain and multispecies probiotics-a comparison of functionality and efficacy. Int. J. Food Microbiol. 2004, 96:219-233.
210. Tissier H. Traitement des infections intestinales par la méthode de la flore bactérienne de l'intestin. C. R. Soc. Biol. 1906, 60:359.
211. Turnbaugh P.J., Hamady M., Yatsunenko T., Cantarel B.L., Duncan A., Ley R.E., Sogin M.L., Jones W.J., Roe B.A., Affourtit J.P., Egholm M., Henrissat B., Heath A.C., Knight R., Gordon J.I. A core gut microbiome in obese and lean twins. Nature 2009, 457(7228):480-484. 10.1038/nature07540.
212. Tursi A., Brandimarte G., Papa A., Giglio A., Elisei W., Giorgetti G.M., Forti G., Morini S., Hassan C., Pistoia M.A., Modeo M.E., Rodino' S., D'Amico T., Sebkova L., Sacca' N., Di Giulio E., Luzza F., Imeneo M., Larussa T., Di Rosa S., Annese V., Danese S., Gasbarrini A. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am. J. Gastroenterol. 2010, 105(10):2218-2227. doi:10.1038/ajg.2010.218.
213. van Belkum A., Nieuwenhuis E.E. Life in commercial probiotics. FEMS Immunol. Med. Microbiol. 2007, 50:281-283.
214. van der Aa L.B., van Aalderen W.M., Heymans H.S., Henk Sillevis Smitt J., Nauta A.J., Knippels L.M., Ben Amor K., Sprikkelman A.B. Synbiotics prevent asthma-like symptoms in infants with atopic dermatitis. Allergy 2011, 66:170-177. Synbad Study Group.
215. van Nimwegen F.A., Penders J., Stobberingh E.E., Postma D.S., Koppelman G.H., Kerkhof M., Reijmerink N.E., Dompeling E., van den Brandt P.A., Ferreira I., Mommers M., Thijs C. Mode and place of delivery, gastrointestinal microbiota, and their influence on asthma and atopy. J. Allergy Clin. Immunol. 2011, 128. 948.55.e1-3.
216. Van Tassell M.L., Miller M.J. Lactobacillus adhesion to mucus. Nutrients 2011, 3:613-636.
217. Vandenbergh P.A. Lactic acid bacteria, their metabolic products and interference with microbial growth. FEMS Microbiol. Rev. 1993, 12:221-238.
218. Vandenplas Y., Veereman-Wauters G., De Greef E., Peeters S., Casteels A., Mahler T., Devreker T., Hauser B. Probiotics and prebiotics in prevention and treatment of diseases in infants and children. J. Pediatr. (Rio J) 2011, 87(4):292-300. Epub 2011 Jul 8. doi:10.2223/JPED.2103.
219. Vaziri N.D., Yuan J., Nazertehrani S., Ni Z., Liu S. Chronic kidney disease causes disruption of gastric and small intestinal epithelial tight junction. Am. J. Nephrol. 2013, 38:99-103.
220. Veerappan G.R., Betteridge J., Young P.E. Probiotics for the treatment of inflammatory bowel disease. Curr. Gastroenterol. Rep. 2012, 14:324-333. PMID: 22581276. 10.1007/s11894-012-0265-5.
221. Vélez M.P., De Keersmaecker S.C., Vanderleyden J. Adherence factors of Lactobacillus in the human gastrointestinal tract. FEMS Microbiol. Lett. 2007, 276:140-148.
222. Venturi A., Gionchetti P., Rizzello F., Johansson R., Zucconi E., Brigidi P., Matteuzzi D., Campieri M. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment. Pharmacol. Ther. 1999, 13(8):1103-1108.
223. Vijanen M., Savilahti E., Haahtela T., Juntunen-Backman K., Korpela R., Poussa T., Tuure T., Kuitunen M. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy 2005, 60(4):494-500.
224. Vimala Y., Dileep P. Some aspects of probiotics. Indian J. Microbiol. 2006, 46:1-7.
225. Vitali B., Cruciani F., Baldassarre M.E., Capursi T., Spisni E., Valerii M.C., Candela M., Turroni S., Brigidi P. Dietary supplementation with probiotics during late pregnancy: outcome on vaginal microbiota and cytokine secretion. BMC Microbiol. 2012, 12:236.
226. Vitetta L., Alford H. The pharmacobiotic potential of the gastrointestinal tract micro-biometabolome-probiotic connect: a brief commentary. Drug Dev. Res. 2013, 74:353-359.
227. Vitetta L., Linnane A.W., Gobe G.C. From the gastrointestinal tract (GIT) to the kidneys: live bacterial cultures (probiotics) mediating reductions of uremic toxin levels via free radical signaling. Toxins 2013, 5:2042-2057. 10.3390/toxins5112042.
228. Voltan S., Castagliuolo I., Elli M., Longo S., Brun P., D'Incà R., Porzionato A., Macchi V., Palù G., Sturniolo G.C., Morelli L., Martines D. Aggregating phenotype in Lactobacillus crispatus determines intestinal colonization and TLR2 and TLR4 modulation in murine colonic mucosa. Clin. Vaccine Immunol. 2007, 14:1138-1148.
229. von Ossowski I., Reunanen J., Satokari R., Vesterlund S., Kankainen M., Huhtinen H., Tynkkynen S., Salminen S., de Vos W.M., Palva A. Mucosal adhesion properties of the probiotic Lactobacillus rhamnosus GG SpaCBA and SpaFED pilin subunits. Appl. Environ. Microbiol. 2010, 6:2049-2057.
230. von Ossowski I., Satokari R., Reunanen J., Lebeer S., De Keersmaecker S.C., Vanderleyden J., de Vos W.M., Palva A. Functional characterization of a mucus-specific LPXTG surface adhesin from probiotic Lactobacillus rhamnosus GG. Appl. Environ. Microbiol. 2011, 77:4465-4472.
231. Watanabe S., Narisawa Y., Arase S., Okamatsu H., Ikenaga T., Tajiri Y., Kumemura M. Differences in fecal microflora between patients with atopic dermatitis and healthy control subjects. J. Allergy Clin. Immunol. 2003, 111:587-591.
232. Williams C., McColl K.E. Review article: proton pump inhibitors and bacterial overgrowth. Aliment. Pharmacol. Ther. 2006, 23(1):3-10.
233. Woo S.I., Kim J.Y., Lee Y.J., Kim N.S., Hahn Y.S. Effect of Lactobacillus sakei supplementation in children with atopic eczema-dermatitis syndrome. Ann. Allergy Asthma Immunol. 2010, 104(4):343-348. doi:10.1016/j.anai.2010.01.020.
234. Yan F., Cao H., Cover T.L., Whitehead R., Washington M.K., Polk D.B. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 2007, 132:562-575.
235. Yan F., Polk D.B. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J. Biol. Chem. 2002, 277:50959-50965.
236. Yang H.-J., Min T.K., Lee H.W., Pyun B.Y. Efficacy of probiotic therapy on atopic dermatitis in children: a randomized, double-blind, placebo-controlled trial. Allergy Asthma Immunol. Res. 2014, 6(3):208-215. pISSN 2092-7355, eISSN 2092-7363. doi:10.4168/aair.2014.6.3.208.
237. Young V.B., Schmidt T.M. Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. J. Clin. Microbiol. 2004, 42:1203-1206.
238. Zyrek A.A., Cichon C., Helms S., Enders C., Sonnenborn U., Schmidt M.A. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKC redistribution resulting in tight junction and epithelial barrier repair. Cell. Microbiol. 2007, 9:804-816.